The National Agency for the Safety of Medicines in France announced that it has approved a drug to treat endometrial cancer and said that the "early access" to the drug "Jemperli" manufactured from the molecule dostarlimab "has been available since October 23 for women with advanced endometrial cancer, whether newly diagnosed or recurrent."

It is worth noting that endometrial cancer usually affects women after menopause and initially appears in the layer of cells that form the inner lining of the uterus. It is considered one of the most common types of cancer, with about ten thousand cases annually in France.

Although the hope of treating it is relatively better compared to other gynecological cancers such as cervical and ovarian cancer, it still causes a large number of deaths.

The health authorities in other countries, including the United States at the end of summer, have previously approved the drug "Jemperli" which must be given in conjunction with chemotherapy.

The European Medicines Agency is still reviewing the file of this drug and has not made a decision yet.

Meanwhile, the French National Agency for the Safety of Medicines granted access to this drug before obtaining the European green light, but with restrictions on prescriptions involved in the early access mechanism, as only doctors specializing in oncology are allowed to prescribe it, with close attention to monitoring side effects.

However, the French agency expressed its belief that the use of "Jemperli" in treating endometrial cancer is characterized by "efficacy and safety."